5 withdrawn, 2 terminated, 1 completed. 8 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Withdrawn 5, Terminated 2, Completed 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow Cornerstone Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) CPI 613, Metformin, Blood draws - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2024-12-01 | 2024-09-19 | |
| Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer CPI-613, modified Folfirinox - Pancreatic Cancer Stage IV | Phase 2 | Withdrawn | Cornerstone Pharmaceuticals | 2024-08-15 | 2024-08-15 | |
| To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue CPI-613 + Hydroxychloroquine - Sarcoma, Clear Cell | Phase 1 / Phase 2 | Completed | Cornerstone Pharmaceuticals | 16 | 2021-09-01 | 2023-05-24 |
| CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer CPI-613, mFOLFIRNOX - Pancreatic Ductal Adenocarcinoma | Phase 2 | Withdrawn | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2018-08-01 | 2025-04-29 | |
| Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome CPI-613 - Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) | Phase 2 | Withdrawn | Cornerstone Pharmaceuticals | 2016-01-01 | 2016-12-29 | |
| Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer CPI-613, Gemcitabine, Any non-gemcitabine chemotherapies or best supportive care - Metastatic Pancreatic Adenocarcinoma | Phase 2 | Withdrawn | Cornerstone Pharmaceuticals | 2014-01-01 | 2013-08-14 | |
| Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients CPI-613 - Cancer | Phase 2 | Terminated | Cornerstone Pharmaceuticals | 7 | 2013-06-01 | 2016-12-29 |
| A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients CPI-613, Gemcitabine - Cancer, Pancreatic Cancer | Phase 1 / Phase 2 | Terminated | Cornerstone Pharmaceuticals | 6 | 2009-05-01 | 2017-03-21 |
Neoplasms (3) · Leukemia, Myeloid, Acute (2) · Neoplasm Metastasis (2) · Pancreatic Neoplasms (2) · Adenocarcinoma (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Colonic Neoplasms (1) · Esophageal Neoplasms (1) · Lung Neoplasms (1) · Myelodysplastic Syndromes (1) · Recurrence (1) · Sarcoma, Clear Cell (1) · Sarcoma, Myeloid (1) · Stomach Neoplasms (1)
devimistat (8) · Gemcitabine (2) · Blood Specimen Collection (1) · Hydroxychloroquine (1) · Metformin (1)
United States (6)
King C Lee, Ph.D. (3) · Avi Retter, M.D. (1) · Bayard Powell, MD (1) · Jordan Winter, MD (1) · Neil Senzer, M.D. (1)
P30CA012197 (1)